10
NEWS
Study backs next-gen
insulin pump
Medtronic has announced positive results from a study of its next-generation
MiniMed 780G automated insulin delivery system.
Its ADAPT study enlisted 82 individuals with Type 1 diabetes who were
not currently meeting glycaemic targets. Half of the sample remained on
standard care, while the rest transitioned to using the MiniMed 780G.
Results demonstrated improvements in glycaemic targets for those using the
MiniMed 780G, including a significant and sustained 1.4% HbA1C reduction
at six months, a 27.6% increase in time in range and no increase in time in
hypoglycaemia.
"The ADAPT study illustrates that insulin pump therapy with advanced
algorithms, like that of the MiniMed 780G system, can produce significantly
improved clinical results versus the current standard of care," said Dr. Ohad
Cohen, senior global medical affairs director, Medtronic Diabetes. "Studies like
this can change how health care systems define standard of care and expand
options for people living with diabetes to begin using insulin pumps sooner to
AdoShell Islets for T1D
French company Adocia has announced the establishment of a first proof of
concept for its' AdoShell Islets implant by achieving glycaemic control without
insulin injections or immunosuppression in diabetic rats, following a 132-day
study.
AdoShell Islets is an immuno-protective synthetic biomaterial containing
islets of Langerhans. After implantation in diabetic animals, the islets
encapsulated in AdoShell secreted insulin in response to blood glucose levels.
The weight gain of the studied rats - which is also an important clinical
indicator of healthy test subjects - showed that the AdoShell Islets were
performing as expected. At the end of the study, the graft was removed, which
resulted in an observable drop of insulin secretion and rise in blood sugar
levels, with the animals rapidly returning to their diabetic state.
"Adocia's results are remarkable, having successfully performed the
first islet transplantation without the use of immunosuppressants in
immunocompetent animals. We are delighted to be actively involved in these
unprecedent results," said Dr. Karim Bouzakri, Director of CEED (European
Center for the Study of Diabetes).
AdoShell Islets will be further evaluated in diabetic pigs at the end of 2022.
Adocia is based in Lyon, France.
Dexcom on
Garmin
After receiving an FDA green light
for the project earlier this year,
Dexcom is now making its diabetes
data available through consumer
electronic devices.
Leading the way is Garmin,
with apps that can display a
person's blood sugar levels taken
from Dexcom's G6 continuous
glucose monitors on devices such
as watches designed for runners
as well as cycling computers that
strap to a bike's handlebars.
"Users can not only see which
way their glucose levels are
trending without having to take
their phone out but can even
do so while working out, when
glucose levels have the potential
to fluctuate quickly," said Dan
Bartel, Garmin's vice president of
worldwide sales.
Diabetes island in Nintendo
game
Nintendo's Animal Crossing game is getting a new diabetes-themed island
designed by medtech company Insulet. This latest move towards 'gamification'
sees diabetes charities teaming up with Insulet to "bring diabetes
representation" to the popular Nintendo game, in which users can add a new
diabetes-themed island, known as Omnipod Bay, which features booths from
selected diabetes charities, as well as inclusive outfits and diabetes-themed
areas and activities.
Low Vit D &
inflammation
A new study has found that vitamin
D deficiency has a causative role
in the systemic inflammation
that commonly accompanies it,
with inflammation declining as
vitamin D levels increase to normal
levels, reflected by reductions
in elevated C-reactive protein
(CRP). The results therefore
suggest that improving vitamin
D status may reduce chronic
inflammation, but only for people
with vitamin D deficiency.